Lupin signs second partnership for its oncology pipeline, this time with German drug maker BI

BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially treat patients of skin and stomach cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2zNFavY
via IFTTT